In the introduction I didn't understand the paragraph "Under normal circumstances, virtually all proinsulin is cleaved at residues 32-33 and 65-66 to produce insulin. Some proinsulin may be released into the circulation, mainly as intact proinsulin, des 31-32 split proinsulin and 32-33 split proinsulin." This must be clarified.
The methods section what's the rationale of taking blood samples after 30 minutes of glucose load? this must be explained it needs to specifically refer to NICE as the international readership may not be completely clear. Methods 1. I do not understand the criteria used for inclusion -factors identified for screening for GDM with specific reference to ethnicity. This is therefore not NICE criteria. I suspect this may be a choice made based on local clinical practice. The rationale of this should be reported. 2. I note that GDM screening will also be performed at 16-18 weeks. I suspect these results will be blinded? This needs to be specified.
VERSION 1 -AUTHOR RESPONSE
Response: This has now been included Reviewer(s) Reports:
Reviewer: 1
Response: This paragraph has been changed to clarify the statement. The paragraph now reads: "Proinsulin is a precursor molecule for insulin and is synthesised by the pancreatic β-cells. Proinsulin is an 86 amino acid peptide, incorporating the A and B chains of insulin in addition to C-peptide between amino acid residues 31 and 65. Under normal circumstances, virtually all proinsulin is cleaved at residues 32-33 and 65-66 to produce C-peptide and insulin, although a small amount of intact proinsulin may also be released into the circulation along with des 31-32 split proinsulin and 32-33 split proinsulin. In the presence of insulin resistance, pancreatic beta-cell function is affected with disproportionately more proinsulin (both intact and split) being secreted compared to insulin as seen in subjects with T2DM [9] ."
The methods section what's the rationale of taking blood samples after 30 minutes of glucose load? this must be explained Response: An additional blood sample was taken at 30 minutes to inform the secondary objectives. The 30 minute and 1 hour timepoints were selected in an attempt to capture the peak postprandial response. In addition, these additional samples will also allow a robust estimation of insulin sensitivity. Introduction 1. Need to be specific which criteria is used for screening for GDM -it needs to specifically refer to NICE as the international readership may not be completely clear.
Response: NICE (2015) criteria will be used and this has been included in the Introduction. Methods 1. I do not understand the criteria used for inclusion -factors identified for screening for GDM with specific reference to ethnicity. This is therefore not NICE criteria. I suspect this may be a choice made based on local clinical practice. The rationale of this should be reported.
Response: The inclusion criteria are based on NICE (2015), although we have not included ethnicity as an inclusion factor for the study due the low rate of ethnicity in the study area. People from ethnic minorities will not be excluded but it will be difficult to isolate the contribution of the risk from ethnicity from the other factors and therefore we have not made it a feature of this study.
2. I note that GDM screening will also be performed at 16-18 weeks. I suspect these results will be blinded? This needs to be specified.
Response: These results will not be blinded. All subjects who exceed the NICE (2015) OGTT thresholds for GDM at 16 -18 weeks will be withdrawn from the study and results will immediately be reported back to the ante-natal team for follow up. All those who remain in the study after visit 1 will be aware that they do not have GDM at that stage as they will be continuing in the study.
